Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for depression comorbid with cancer
2020-005037-32Phase 2Active
- Sponsor
- National Institute of Mental Health, Czech Republic
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and cancer comparing Psilocybin arm, Ketamine arm and Midazolam control arm (3 arms). Primary endpoint: Efficacy of psilocybin at 4 weeks. Started Dec 2020; status: active.
02
Drugs
psilocybinketaminemidazolam
03
Conditions
major depressive disorder (MDD)cancer
Beyond the preview
Go deeper on 2020-005037-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005037-32.